Company Overview
The Almac Group is an established contract development and manufacturing organization that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Japan).

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs. Only Almac can combine the expertise from our specialized teams to provide you with the right service solutions to help you across the full biopharmaceutical product lifecycle, from development through to commercialization.

**Integrated CMC Services:

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, from a single campus, resulting in significant savings in both time and costs.

Integrated teams within Chemical and Pharmaceutical Development work closely to fully understand the physicochemical properties of the API to ensure the optimum chemical entity is available for the manufacture of clinical supplies. We routinely apply our innovative biocatalysis technology solutions which are beyond the traditional realms of chemical synthesis. This provides new and attractive synthesis options which are fully scalable, safe and economic.

Whether your requirements are for First in Human supplies or later phase development, manufacture or registration batches, Almac have access to a wide range of innovative technologies for both potent and non-potent solid oral dose products.

Having both chemical and pharmaceutical development operations at the same campus, allows for optimal communication and knowledge transfer on projects. Our clients leverage this integrated service offering, exploiting the Almac advantage of a single partner approach. Smoothing transition through the drug development process and ultimately commercialisation saves time, transfers and other uncertainties inherent in a multi-supplier multi-site process.

Through our continued investment in the expansion of our state-of-the-art services; from new world-class, 220,000ft2 pharmaceutical development facilities and new analytical laboratories hosting upgraded mass spec and ICPMS capabilities, through to specialised packaging solutions supporting complex kit assembly and serialisation, Almac ensures we are always there to support you across the product development lifecycle.

5:00 PM–6:30 PM Jun 5, 2018 (US - Eastern)

Exhibit Halls A-C


4:30 PM–5:30 PM Jun 6, 2018 (US - Eastern)